13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001121404
Total reported value
$534.0M
$534.0M
10 檔
31.3%
During the Q2 2025 filing period, Sanofi (CIK: 0001121404) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $534.0M across 10 reported positions.
During Q2 2025, Sanofi's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MGTX | MeiraGTx Holdings plc | Stock-Other | 45.25% | -0.58% | — | |
| 2 | NVAX | Novavax Inc | Stock-Healthcare | 24.67% | -4.53% | — | |
| 3 | ANAB | Anaptysbio Inc | Stock-Other | 10.38% | +1.35% | — | |
| 4 | INBX | Inhibrx Biosciences Inc | Stock-Other | 9.40% | -2.63% | — | |
| 5 | OMDA | Omada Health Inc | Stock-Other | 5.47% | — | — | |
| 6 | ✓ | Lava Therapeutics NV | Stock-Other | 1.44% | — | — | |
| 7 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 1.26% | -0.75% | EXIT | |
| 8 | ✓ | Inozyme Pharma Inc | Stock-Other | 1.01% | — | — | |
| 9 | 1K0 | Igm Biosciences Inc | Stock-Other | 0.92% | — | — | |
| 10 | QTTB | Q32 Bio Inc | Stock-Other | 0.21% | +0.11% | — |
According to official SEC Form 13F filings, Sanofi reported a total U.S. public equity portfolio value of $534.0M across 10 disclosed positions in Q2 2025.
During Q2 2025, Sanofi's top holdings by market value included MGTX (45.3%)、NVAX (24.7%)、ANAB (10.4%). The largest single position, MGTX, represented 45.3% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MGTX, NVAX, ANAB) accounted for 31.3% of total reported equity market value during Q2 2025.
In Q2 2025, Sanofi made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.